Generic Launches

Reference Listed Drug, NDA Holder, Generic Drug Name, ANDA Applicant(s), Indication and Launch Date

Summer 2014

GENERICally Speaking: A Hatch Waxman Litigation Bulletin
Reference Listed Drug NDA Holder Generic Drug Name ANDA
Applicant(s)
Indication Launch Date

Taclonex

Leo Pharma

Calcipotriene / Betamethasone Dipropionate Ointment

Sandoz

Topical treatment of psoriasis vulgaris

4/1/2014

 

Taclonex

Leo Pharma

Calcipotriene / Betamethasone Dipropionate Ointment

Perrigo

Topical treatment of psoriasis vulgaris

4/1/2014

 

Ten-K

Novartis

Potassium Chloride Extended-release Capsules

Par Pharm

Hypokalemia with or without metabolic alkalosis, in digitalis intoxications, hypokalemic familial periodic paralysis

4/7/2014

 

Lovaza

GlaxoSmithKline

Omega-3-Acid Ethyl Esters Capsules, USP

Teva

Adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia

4/8/2014

 

Lunesta

Sunovion Pharms

Eszopiclone Tablets

Dr. Reddy's Labs

Insomnia

4/15/2014

 

Lunesta

Sunovion Pharms

Eszopiclone Tablets

Mylan

Insomnia

4/15/2014

 

Lunesta

Sunovion Pharms

Eszopiclone Tablets

Teva

Insomnia

4/15/2014

 

Lunesta

Sunovion Pharms

Eszopiclone Tablets

Glenmark Generics

Insomnia

4/15/2014

 

Ortho Evra

Janssen Pharms

Norelgestromin / Ethinyl Estradiol Transdermal System

Mylan

Prevention of pregnancy

4/16/2014

 

Antara

Lupin

Fenofibrate Capsules

Dr. Reddy's Labs

Cholesterol

4/23/2014

 

Differin

Galderma Labs

Adapalene gel

Sandoz

Topical treatment of acne vulgaris in patients 12 years of age and older

4/28/2014

 

Catapres-TTS

Boehringer Ingelheim

Clonidine Transdermal System

Actavis

Hypertension

5/7/2014

 

Astepro

Media Pharms

Azelastine hydrochloride nasal spray (0.15%)

Perrigo / Impax Labs

Nasal symptoms caused by seasonal allergies or environmental irritants

5/12/2014

 

Exalgo

Mallinckrodt

Hydromorphone Hydrochloride Extended-release Tablets

Actavis

Moderate to severe pain in opioid tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time

5/13/2014

 

Zyprexa Zydis

Eli Lilly

Olanzapine Orally Disintegrating Tablets

Mylan

Schizophrenia or the acute treatment of manic or mixed episodes associated with bipolar I disorder and maintenance treatment of bipolar I disorder

5/14/2014

 

Malarone

GlaxoSmithKline

Atovaquone / Proguanil Hydrochloride

Mylan

Prophylaxis of plasmodium falciparum malaria and the treatment of acute, uncomplicated P. falciparum malaria

5/29/2014

 

Paraplatin

Bristol-Myers Squibb

Carboplatin Injection

Mylan

Advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents

6/9/2014

 

Actonel

Warner Chilcott

Risedronate Sodium Tablets

Mylan

Osteoporosis in postmenopausal women

6/11/2014

 

Cipro

Bayer Healthcare

Ciprofloxacin for Oral Suspension

Lupin Pharms

Infections caused by susceptible isolates of the designated microorganisms in various conditions and patient populations

6/13/2014

 


Related Publications

Fourth Quarter
GENERICally Speaking: A Hatch-Waxman Litigation Bulletin
Oren Langer, Christopher Pinahs, Emily Tremblay, and Christine May
December 29, 2023
Corcept Therapeutics, Inc. v. Teva Pharms. USA, Inc.
GENERICally Speaking Hatch Waxman Bulletin
December 13, 2023
Acadia Pharms. Inc. v. Aurobindo Pharma Ltd.
GENERICally Speaking Hatch Waxman Bulletin
December 7, 2023
H. Lundbeck A/S v. Lupin Ltd.
GENERICally Speaking Hatch Waxman Bulletin
November 7, 2023
Eisai R&D Mgmt. Co., Ltd. v. Dr Reddy’s Labs., Inc.
GENERICally Speaking Hatch Waxman Bulletin
Back to Top